Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TIM-1 and Tiny-TIM as Robust In Vitro Models for Oral Biopharmaceutics: Evidence from an International Ring Study.

Pharmaceutics·2026
Same author

The In Vivo Effect of Amorphous Drug Nanoprecipitates on the Intestinal Absorption of the PROTACs ARV-110 (Bavdeglutamide) and ARV-471 (Vepdegestrant).

Molecular pharmaceutics·2026
Same author

Endovascular-assisted microsurgical clipping of ophthalmic segment aneurysms.

Acta neurochirurgica·2026
Same author

Exploring Digestion-Induced Fed-State Simulated Intestinal Media with a Lipid Fraction and Compositional Variability.

The AAPS journal·2026
Same author

Oleic acid-based formulation enables drug delivery of bRo5 compounds through intestinal lymphatic absorption.

International journal of pharmaceutics·2026
Same author

An Expert's View on the Application of TIM Technology in the Development of Oral Drug Products.

Molecular pharmaceutics·2026
Same journal

Erratum to "'Site-specific enrichment of highly sialylated N-glycans in an erythropoietin-hybrid Fc fusion protein" [Eur. J. Pharm. Biopharm. 226 (2026) 115147].

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same journal

Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same journal

DNA network-encapsulated carnosine/ZnO nano-complexes for enhanced antibacterial efficacy and biocompatibility.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same journal

Green synthesized β-caryophyllene oxide enriched fraction-derived carbon quantum dots trigger ROS production and p53 activation in HepG2 cells.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same journal

Novel approach for direct drug delivery to the central nervous system via intratympanic administration.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same journal

Hyaluronic acid and PEA-based Rutin-loaded nanoparticles as new cardioprotective tool against anthracycline-induced cardiotoxicity.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
See all related articles
  1. Home
  3. Exploring Formulation Options For Extended Release Minitablets.
  1. Home
  3. Exploring Formulation Options For Extended Release Minitablets.

Related Experiment Video

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

Exploring formulation options for extended release minitablets.

Esther Bochmann1, Eugenia Eugenia-Ilieva2, Stephan Heil2

  • 1Abbvie Deutschland GmbH & Co. KG, Drug Product Design & Development, Ludwigshafen, Germany.

European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V
|June 9, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Developing extended-release (ER) minitablets for Compound A, a challenging BCS class II drug, was achieved. Optimized formulations maintained drug plasma concentrations for 24 hours, offering a novel approach for ER minitablet development.

Keywords:
Biorelevant methodsDissolutionExtended releaseFormulation developmentMelt granulationMinitabletsModified releaseWet granulation

More Related Videos

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

Related Experiment Videos

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

Area of Science:

  • Pharmaceutical Technology
  • Drug Delivery Systems
  • Formulation Development

Background:

  • Minitablets offer advantages over conventional tablets, particularly for patients with swallowing difficulties.
  • Developing extended-release (ER) dosage forms using minitablets presents significant formulation challenges.
  • Compound A, a BCS class II drug with pH-dependent solubility, requires careful formulation for sustained release.

Purpose of the Study:

  • To develop extended-release (ER) minitablet formulations for Compound A to achieve 24-hour drug plasma concentrations.
  • To investigate the influence of API form, matrix formers, and release components on drug release profiles.
  • To establish a material-sparing development pathway for ER minitablets.

Main Methods:

  • Formulation screening of ER minitablets using wet or melt granulation techniques.
  • Dissolution testing based on compendial methods for high throughput screening.
  • Biorelevant testing using a multi-stage dissolution test to assess drug release at physiological pH.

    • Main Results:

    • Successfully developed ER minitablets capable of maintaining Compound A plasma concentrations over 24 hours.
    • Demonstrated that combining specific API forms, hydrophobic matrix formers, and hydrophilic release components is crucial for ER.
    • Validated a novel approach combining material-sparing formulation adjustment and biorelevant testing for ER minitablet development.

    Conclusions:

    • Extended-release (ER) minitablets for Compound A are feasible, addressing challenges related to its physicochemical properties.
    • The developed formulation strategy enables precise control over drug release profiles for 24-hour efficacy.
    • This approach offers a time-efficient and targeted method for developing complex ER minitablet dosage forms.